Clinical and neurobiological effects of NIRS-controlled transcranial magnetic stimulation (rTMS) in patients with panic disorder during cognitive behavioural therapy (CBT) treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006345

Enrollment

Registered

2014-07-21

Start date

2011-01-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F41.0 F40.01

Interventions

Group 1: 9 weeks of CBT - 1.5 hours/week, average group size 5 participants + verum iTBS (intermittend thetaburst stimulation, Huang et al., 2005: 600 pulses applied in intermittent biphasic bursts at

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: DSM-IV Diagnosis of Panic Disorder with or without Agoraphobia

Exclusion criteria

Exclusion criteria: Any severe somatic disorder · Brain organic disorder · Substance abuse disorder · Schizophrenia · Schizoaffective disorder · Bipolar disorder · Severe major depression · Severe Personality Disorders (e.g Borderline personality disorder) · Suicidality · Epilepsy · Cardiac Pacemaker · Any metal parts within the head · past or current benzodiazepine treatment within 3 half-lives before study begin · past or current treatment with anticonvulsiva during the last 3 months · pregnancy

Design outcomes

Primary

Measure	Time frame
clinical symptom severity: measured by means of the German version of the Panic and Agoraphobia scale (PAS; Bandelow, 1997), the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1996) and the Cardiac Anxiety Questionnaire (CAQ; Eifert et al., 2000; Hoyer et al., 2005) at the following dates: - at the begining of rTMS (repetitive transcranial magnetic stimulation) treatment - after the first week of rTMS treatment - after the second week of rTMS treatment - at the end of rTMS treatment - after nine weeks, to say at the end of CBT (cognitive behavioural therapy) - at the first follow-up date three months after the end of CBT - at the second follow-up date six months after the end of CBT	—

Measure

Time frame

clinical symptom severity: measured by means of the German version of the Panic and Agoraphobia scale (PAS; Bandelow, 1997), the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1996) and the Cardiac Anxiety Questionnaire (CAQ; Eifert et al., 2000; Hoyer et al., 2005) at the following dates: - at the begining of rTMS (repetitive transcranial magnetic stimulation) treatment - after the first week of rTMS treatment - after the second week of rTMS treatment - at the end of rTMS treatment - after nine weeks, to say at the end of CBT (cognitive behavioural therapy) - at the first follow-up date three months after the end of CBT - at the second follow-up date six months after the end of CBT

—

Secondary

Measure	Time frame
prefrontal brain activation: measured by means of near-infrared spectroscopy, at the latest 48 hours before the first rTMS treatment and at the earliest 12 hours afte the last rTMS treatment	—

Countries

Germany

Contacts

Public ContactSaskia Deppermann

Klinik für Psychiatrie und Psychotherapie, Tübingen

saskia.deppermann@med.uni-tuebingen.de07071/29 83609

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026